Novo Nordisk’s stock rallied after drugmaker reveals deal with OpenAI

Novo Nordisk is working with OpenAI on a broad deal that will use artificial intelligence to more quickly develop new medications as well as help train its workforce.

​Novo Nordisk is working with OpenAI on a broad deal that will use artificial intelligence to more quickly develop new medications as well as help train its workforce.